Stock Ratings / Health Care / ICCM / options

CODX (29) XAIR (30) AMIX (34) IVF (35) ⌘ Pro Terminal →

IceCure Medical Ltd. (ICCM) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is ICCM trading relative to its 50-day, 200-day, and 52-week technical levels?

ICCM last traded at $0.87 (-9.05% on volume of 50,264 shares), positioning the stock -46.63% below its 50-day simple moving average ($1.63) and -88.89% below its 200-day simple moving average ($7.83). Across its 52-week range of $0.82 to $23.49, ICCM sits at the 0.2% percentile with a 14-day RSI of 28.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.98).

Q: What is ICCM's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ICCM.

$0.87 -9.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.85

IceCure Medical Ltd. (ICCM) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $3.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ICCM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ICCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, IceCure Medical Ltd. (NASDAQ: ICCM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.87 (-9.05% 1D, market cap $3.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ICCM ranks #735 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ICCM compare to CODX and XAIR in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), ICCM carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 36.3%, and ROIC of -35.0%. By comparison, CODX (Co-Diagnostics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M) and XAIR (Beyond Air Inc.) posts a E grade (30/100 RQD, P/E 112.1x, ROIC -35.0%, cap $3.8M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while ICCM leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ICCM?

▼

Per ICCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001584371), IceCure Medical Ltd. generated $3.4M in revenue (+2.7% YoY), -$15.1M in net income, and -$14.6M in free cash flow against $13.9M in total assets and $13.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.85 (-1.82%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ICCM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY ICCM SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 28.5 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.08+0% Next Q

Q2 (-2Q)

Grade E$1.08-4.6% Next Q

Q3 (-1Q)

Grade E$1.03-15.5% Next Q

Current

Grade E$0.87-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ICCM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ICCM currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.63) and Max Pain ($0.91) forces dealer call-delta covering toward $24.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ICCM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ICCM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ICCM)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ICCM.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ICCM)

✓Walkthrough of ICCM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ICCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -90.14%🛡️ HOLDING TREND SUPPORT

2026-11-02O $0.98H $0.98L $0.87C $0.87VOL 56.7K

SUP: $0.52SMA50: $1.63SMA200: $7.83

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ICCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ICCM Butterfly Map → + Track ICCM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +2.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ICCM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ICCM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ICCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ICCM)

Health Care Rank #735 of 1016 ⚔️ CODX vs ICCM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ICCM vs. CODX, XAIR, AMIX, IVF)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, IceCure Medical Ltd. (ICCM) ranks #735 by composite RQD confidence (34/100, grade E) and #977 by equity capitalization ($3.3M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while ICCM leads on capital efficiency and profitability with -35.0% ROIC and 36.3% gross margin. IVF currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with ICCM at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ICCM ACTIVE IceCure Medical Ltd.	E	34/100	—	36.3%	-35.0%	-9.05%	$3.3M	Benchmark Subject
CODX Co-Diagnostics Inc.	E	29/100	—	64.3%	-35.0%	-7.16%	$3.5M	/codx-vs-iccm →
XAIR Beyond Air Inc.	E	30/100	112.1x	3.3%	-35.0%	-3.03%	$3.8M	/xair-vs-iccm →
AMIX Autonomix Medical Inc.	E	34/100	—	—	-35.0%	-11.27%	$4.0M	/amix-vs-iccm →
IVF INVO Fertility Inc.	D-	35/100	—	96.0%	-35.0%	-10.93%	$2.5M	/ivf-vs-iccm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001584371

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IceCure Medical Ltd. (ICCM) reported GAAP revenue of $3.4M (+2.7% vs. FY2024 revenue of $3.3M , and +4.6% cumulative change since FY2023) , GAAP net income of -$15.1M, operating cash flow of -$14.6M, and free cash flow of -$14.6M (-15.6% YoY). On the balance sheet, ICCM closed FY2025 with $13.9M in total assets against $13.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.4M	-$15.1M	-$14.6M	-$14.6M	$13.9M	$13.0K
FY2024 (FY)	2024-12-31	$3.3M	-$15.3M	-$12.6M	-$12.6M	$12.6M	$161.0K
FY2023 (FY)	2023-12-31	$3.2M	-$14.7M	-$12.6M	-$12.6M	—	—

3. ICCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ICCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ICCM compare to CODX and XAIR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ICCM?

Where is ICCM trading relative to its 50-day, 200-day, and 52-week technical levels?

ICCM last traded at $0.87 (-9.05% on volume of 50,264 shares), positioning the stock -46.63% below its 50-day simple moving average ($1.63) and -88.89% below its 200-day simple moving average ($7.83). Across its 52-week range of $0.82 to $23.49, ICCM sits at the 0.2% percentile with a 14-day RSI of 28.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.98).

ICCM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ICCM's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ICCM.

Direct Sub-Reports: ICCM RQD Cockpit ICCM 12M Forecast ICCM Earnings & Move ICCM Dividends & DRIP ICCM Insiders & 13F ICCM Whale Options ICCM Profit Sankey ICCM News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ICCM — IceCure Medical Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:54:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ICCM scores 34 out of 100, a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 6 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. Per the SEC financials, FY 2025 free cash flow was $-14.6M against revenue of $3.4M, so the business is consuming cash rather than generating it. This is the weakest pillar and the core reason the rating is low.
Whale / 13F Flow: 3 / 20. This is the lowest pillar score. The source data contains no 13F holder records, so the score reflects the absence of institutional accumulation signals in the data provided.
Insider Conviction: 5 / 20. The source data contains no Form 4 or Congressional trade records. The low score reflects the absence of insider buying signals.
Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, beta is 1.0 and the stock carries sector sensitivity. The score is mid-range and does not provide a clear tailwind.
Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 5/9, and Debt/Equity is 0.5. Per the SEC financials, FY 2025 debt was $0.0M, which is consistent with the low Debt/Equity figure. The balance sheet is the strongest pillar, but it is only mid-range.

Practical implications for a prospective investor evaluating the stock today: the valuation is anchored to a shrinking equity base (market capitalization of $3.3M per market data), so the upside case depends on the company reaching cash-flow breakeven before its cash balance of $8.9M (FY 2025, per SEC financials) is depleted at the current burn rate. The 52-week range of $0.82 to $23.49 shows extreme drawdown volatility. Per the rating's own verdict, the risk profile is judged forensic and the rating advises avoidance. This brief is educational and does not constitute personalized financial advice.

Business

IceCure Medical Ltd. (ICCM) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry, per the profile. Per the recent news wire, the company is engaged in a breast cancer study involving tumor freezing, with a headline reporting a 97.5% response rate at 12 months across 40 patients when combined with hormone therapy. Per the SEC financials, FY 2025 revenue was $3.4M. Source data does not describe the product line, customer base, or revenue model in further detail.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$3.4M	$-15.1M	$-15.1M	N/A	$-14.6M	$8.9M	$0.0M
FY 2024	$3.3M	$-15.7M	$-15.3M	N/A	$-12.6M	$7.6M	$0.2M
FY 2023	$3.2M	$-15.6M	$-14.7M	N/A	$-12.6M	N/A	N/A

Per the SEC financials, the company reported operating losses in every period shown, with operating margin of -60% and net margin of -60% per market data. Revenue grew modestly from $3.2M to $3.4M across the three periods while losses remained near $15M annually. Per the Roarable RQD rating, ROIC is -35%, Altman Z-Score is 2.5, and Piotroski F-Score is 5/9. Debt was $0.0M in FY 2025 and cash rose to $8.9M, per SEC financials.

Recent Catalysts & News Wire Analysis

Per the recent news wire, six items reference ICCM, all with YELLOW light and MARKET WIRE impact labels, sourced from TradingView, Simply Wall St, Stock Titan, and Benzinga. The headlines reference a study of freezing breast tumors, which per the wire enrolled its first patients and is designed for about 400 participants. A Benzinga item lists ICCM among health care stocks moving in pre-market trading. The wire summaries are generic templates and provide no substantive institutional or fundamental detail. Risk watch items: the study is at an early enrollment stage relative to its design size, and the company's losses continue. Per the Butterfly Supply-Chain Graph, there are no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. A prospective investor should note that the absence of mapped links means this analysis cannot identify supplier or customer concentration from the provided data.

Open Questions

What is the company's cash runway given FY 2025 free cash flow of $-14.6M against cash of $8.9M, and does the balance sheet require new financing?
What are the FY 2023 cash and debt balances, which the source data lists as N/A?
What is the current status and timeline of the breast tumor-freezing study enrollment beyond the first patients?
Why is EPS reported as N/A across all periods, and what is the share count underlying the $3.3M market capitalization?
What is the product and revenue mix driving the $3.4M revenue base?

ICCM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for IceCure Medical Ltd. (ICCM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ICCM Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 3h ago

IceCure Medical Ltd. Estimates – NASDAQ:ICCM

TradingView report covering IceCure Medical Ltd. (ICCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 6h ago

IceCure Medical (NasdaqCM:ICCM) Stock Forecast & Analyst Predictions

Simply Wall St report covering IceCure Medical Ltd. (ICCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 9h ago

At 12 months, tumor-freezing plus hormone therapy had a 97.5% response rate in 40 breast cancer patients.

Stock Titan report covering IceCure Medical Ltd. (ICCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 12h ago

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - SCWorx (NASDAQ:WORX), Integra Lifesciences

Benzinga report covering IceCure Medical Ltd. (ICCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 15h ago

A study of freezing breast tumors enrolled its first patients and is designed for about 400.

Stock Titan report covering IceCure Medical Ltd. (ICCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

A breast cancer study treats its first patient by freezing a tumor

Stock Titan report covering IceCure Medical Ltd. (ICCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 21h ago

IceCure Medical Ltd (ICCM) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering IceCure Medical Ltd. (ICCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

IceCure Medical Ltd Stock Price Today | ICCM Live Chart & News

Traders Union report covering IceCure Medical Ltd. (ICCM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ICCM Bull vs. Bear Conversation Board — What's Your Call at $0.87?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ICCM 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.84 (-12.5%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ICCM (E • RQD 34/100) a Buy at $0.96?

Welcome to the ICCM (IceCure Medical Ltd.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.76 (-20.8%)

Spot @ $0.96

Pump the brakes on ICCM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ICCM, but look at what you are paying: current EV/EBITDA multiples with 36.3% gross margins. Unless IceCure Medical Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.09 (+13.5%)

Spot @ $0.96

ICCM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ICCM, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $0.96 (52-wk range $0.82 - $23.49), any beat on forward guidance forces shorts and underweight funds to chase.